Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea.

Dany Jaffuel Yannick Bouchaut Jean-Pierre Mallet Célia Vidal Nicolas Molinari Arnaud Bourdin Francois Roubille

Published in: ERJ open research (2023)

Dapagliflozin decreases central sleep apnoea in central sleep apnoea patients, thereby sparing the initiation of ventilatory therapy https://bit.ly/41e2fm0.

Keyphrases

ejection fraction
positive airway pressure
end stage renal disease
sleep quality
physical activity
chronic kidney disease
newly diagnosed
obstructive sleep apnea
stem cells
patient reported outcomes
depressive symptoms
drug induced